GlassScriptPhysician profile
Salik Choudhary
NPI 1386986578
$4,181.58
in general payments reported to CMS, 2019-2025
27 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $108 · 2021: $186 · 2022: $716 · 2023: $958 · 2024: $1,541 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806 · Travel and Lodging: $289 · Education: $77.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.82 |
| Travel and Lodging | $289.16 |
| Education | $77.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $968.74 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $618.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $546.62 | 2020-2025 | Tezspire, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $320.45 | 2021-2025 | Dupixent |
| Intuitive Surgical, INC. | $289.16 | 2025 | |
| Insmed, INC. | $252.63 | 2022-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.62 | 2021-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $200.14 | 2022-2024 | Winrevair, Zerbaxa, Recarbrio |
| Electromed, INC. | $168.22 | 2022-2024 | Smartvest |
| Grifols USA, LLC | $86.19 | 2023-2024 | Prolastin-C Liquid |
| Ethicon INC. | $61.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.73 | 2020-2022 | |
| Harmony Biosciences LLC | $39.19 | 2024 | |
| Janssen Pharmaceuticals, INC | $37.82 | 2021-2022 | |
| Philips North America LLC | $36.51 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $25.78 | 2023 | |
| Mylan Specialty L.P. | $25.54 | 2022-2024 | Yupelri |
| Pinnacle Biologics, INC | $25.03 | 2024 | Photofrin |
| Ambu INC. | $23.52 | 2023 | |
| Paratek Pharmaceuticals, INC. | $22.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $21.45 | 2022 | |
| Optinose US, INC. | $20.69 | 2024 | |
| Shionogi INC | $18.17 | 2024 | Fetroja |
| Circassia INC. | $17.37 | 2020 | |
| Baxter Healthcare | $15.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2022 | |
| Axsome Therapeutics, INC. | $14.43 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salik Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.